The 7th Joint ECTRIMS-ACTRIMS Meeting, the world’s largest annual international conference devoted to basic and clinical research in multiple sclerosis, will run from Oct. 25 to 28 in Paris — the city of Jean-Martin Charcot, the “Father of Neurology,” who provided the first detailed description of multiple sclerosis (MS) in 1868.
The meeting’s organizers note in a release that Paris today has an active and dynamic MS network, one that bridges clinical, imaging, genetics, immunology and neurobiology. The conference program ranges from plenary lectures, and discussions of scientific abstracts, to sessions on hot topics and the work of young MS investigators. Numerous scientific posters will also be available for review.
More than 8,000 neurologists, researchers and other leaders in the field are scheduled to attend.
Highlights of the four-day conference include sessions on potential advances in the treatment of progressive MS, prognostic disease markers, the blood-brain barrier, B-cell versus T-cell therapies, the gut microbiota, treatment burden and how it might be eased, and insights into long-term disability as seen in patients groups in clinical trials.
Themes addressed will include recent advances in neurobiology and neuro-immunology, new diagnostic criteria, MS biomarkers, disease management, the latest clinical trials results, and emerging strategies to promote repair of neural pathways.
The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is an independent, European-wide organization and the world’s largest professional organization dedicated to the understanding and treatment of MS.
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), founded in 1995, is a community of leaders from the United States and Canada specialized in MS and other demyelinating diseases.
The French MS Society, known as ARSEP, is the meeting’s local organizer, and is also sponsoring a Patient Day on Tuesday, Oct. 24, at the Hyatt Hotel in Paris. Starting at 1 p.m., MS specialists will speak to patients on recent research and treatments in multiple sclerosis, and an open exchange between patients and researchers is welcome. Patient Day discussions will be held in French. More information, also in French, is available through this link.
Those unable to attend MSParis2017 are invited to join the discussion via social media, and take part in the congress online. Anyone can follow each day’s events either via @ectrims, the official ECTRIMS Twitter account, or its official Facebook page.
All tweets regarding the congress, including the scientific program, will be posted under the hashtag #MSParis2017.
Multiple Sclerosis News Today will be covering the 7th Joint ECTRIMS – ACTRIMS meeting, offering its readers daily summaries of the latest advances and discoveries in MS research.
For more information, visit: